Evidence map›Paper›PMID 33679747›Full record

ArticleFrontiers in immunology2021

Esther Giehl, Hiromichi Kosaka, Zuqiang Liu, Mathilde Feist, Udai S Kammula, Michael T Lotze, Congrong Ma, Zong Sheng Guo, David L Bartlett

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Primary and metastatic peritoneal surface malignancies.Nature reviews. Disease primers · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Esther GiehlDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Hiromichi KosakaDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Zuqiang LiuDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Mathilde FeistDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Udai S KammulaDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Michael T LotzeDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Congrong MaDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Zong Sheng GuoDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
David L BartlettDepartments of Surgery, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
UPMC Hillman Cancer Center · USCharité - Universitätsmedizin Berlin · DEKyowa Kirin (Japan) · JPUniversity Hospital Carl Gustav Carus · DE

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
Metabolic Reprogramming of Tumor Infiltrating Lymphocytes for Adoptive ImmunotherapyR01CA233521 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMMULA, UDAI S · 2019 to 2023
$1.8M
NCI NIH HHS P30 CA047904NCI NIH HHS R01 CA233521
6 · The paper itself

Abstract

Adoptive cell therapy (ACT) using autologous tumor infiltrating lymphocytes (TIL) achieves durable clinical benefit for patients from whom these cells can be derived in advanced metastatic melanoma but is limited in most solid tumors as a result of immune escape and exclusion. A tumor microenvironment (TME) priming strategy to improve the quantity and quality of TIL represents an important tactic to explore. Oncolytic viruses expressing immune stimulatory cytokines induce a potent inflammatory response that may enhance infiltration and activation of T cells. In this study, we examined the ability of an attenuated oncolytic vaccinia virus expressing IL15/IL15Rα (vvDD-IL15/Rα) to enhance recovery of lavage T cells in peritoneal carcinomatosis (PC). We found that intraperitoneal (IP) vvDD-IL15/Rα treatment of animals bearing PC resulted in a significant increase in cytotoxic function and memory formation in CD8

Indexed as

Immunotherapy, AdoptiveAnimalsCell Line, TumorDisease Models, AnimalGenetic VectorsHumansImmunophenotypingInterleukin-15Interleukin-15 Receptor alpha SubunitLymphocyte ActivationLymphocytes, Tumor-InfiltratingMiceOncolytic VirotherapyOncolytic VirusesPeritoneal NeoplasmsT-Lymphocytes, CytotoxicInterleukin-15Interleukin-15 Receptor alpha Subunitadoptive cell therapy (ACT)CD8+ T cellsIL-15oncolytic virussolid tumor

Identifiers

PMID33679747
PMCPMC7930493
OpenAlexW3132008416

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.